View Filing Data

Condensed Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 10,270	$ 12,066
Accounts receivable, net		473
Inventory	1,709	380
Prepaid expenses and other current assets	844	2,090
Total current assets	12,823	15,009
Property and equipment, net	938	1,117
Intangible assets, net	650	725
Operating lease right-of-use assets, net	96	160
Other long-term assets, net	52	61
Total assets	14,559	17,072
Current liabilities:
Accounts payable	1,953	575
PPP loan, current portion	159
Accrued liabilities	627	1,388
Total current liabilities	2,739	1,963
Long-term debt, net of discount and including accrued fees	4,587	4,540
Long-term portion of PPP loan	202
Operating lease liabilities, net of current portion		19
Total liabilities	7,528	6,522
Commitments and contingencies (Note 11)
Stockholders' equity
Common stock, $0.001 par value; 50,000,000 shares authorized as of June 30, 2020 and December 31, 2019; 20,956,033 and 17,877,486 shares issued and outstanding at June 30, 2020 and December 31, 2019, respectively	21	18
Additional paid-in capital	84,977	74,720
Accumulated deficit	(77,967)	(64,188)
Total stockholders' equity	7,031	10,550
Total liabilities and stockholders' equity	$ 14,559	$ 17,072

Condensed Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Revenues:
Total revenues	$ 20		$ 119	$ 500
Cost of product sales	28		130
Gross (loss) profit	(8)		(11)	500
Operating expenses:
Research and development	1,609	1,439	7,877	7,904
General and administrative	2,921	1,910	5,531	3,499
Total operating expenses	4,530	3,349	13,408	11,403
Loss from operations	(4,538)	(3,349)	(13,419)	(10,903)
Other (expense) income:
Interest and other (expense) income, net	(192)	100	(360)	244
Loss before income tax expense	(4,730)	(3,249)	(13,779)	(10,659)
Income tax expense
Net Loss	$ (4,730)	$ (3,249)	$ (13,779)	$ (10,659)
Net loss per share, basic and diluted	$ (0.23)	$ (0.18)	$ (0.70)	$ (0.61)
Weighted average number of common shares outstanding, basic and diluted	21,005	17,733	19,574	17,618
Product Sales [Member]
Revenues:
Total revenues	$ 20		$ 119
Licensing Revenue [Member]
Revenues:
Total revenues				$ 500

Condensed Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Total
Balance at Dec. 31, 2018	$ 18	$ 72,153	$ (45,868)	$ 26,303
Balance, shares at Dec. 31, 2018	17,607,928
Stock-based compensation		850		850
Stock-based compensation, shares
Stock option exercises		77		77
Stock option exercises, shares	90,000
Employee stock purchase plan		128		128
Employee stock purchase plan, shares	23,083
Stock warrant exercises
Stock warrant exercises, shares	42,034
Net loss			(10,659)	(10,659)
Balance at Jun. 30, 2019	$ 18	73,208	(56,527)	16,699
Balance, shares at Jun. 30, 2019	17,763,045
Balance at Mar. 31, 2019	$ 18	72,502	(53,278)	19,242
Balance, shares at Mar. 31, 2019	17,627,928
Stock-based compensation		505		505
Stock-based compensation, shares
Stock option exercises		73		73
Stock option exercises, shares	70,000
Employee stock purchase plan		128		128
Employee stock purchase plan, shares	23,083
Stock warrant exercises
Stock warrant exercises, shares	42,034
Net loss			(3,249)	(3,249)
Balance at Jun. 30, 2019	$ 18	73,208	(56,527)	16,699
Balance, shares at Jun. 30, 2019	17,763,045
Balance at Dec. 31, 2019	$ 18	74,720	(64,188)	10,550
Balance, shares at Dec. 31, 2019	17,877,486
Stock-based compensation		1,079		1,079
Stock-based compensation, shares	15,190
Stock option exercises		97		97
Stock option exercises, shares	69,878
Employee stock purchase plan		64		64
Employee stock purchase plan, shares	14,005
Proceeds from sales of common stock, net of offering costs	$ 3	7,753		7,756
Proceeds from sales of common stock, net of offering costs, shares	2,600,000
Issuance of common stock for product candidate licensing rights		1,264		1,264
Issuance of common stock for product candidate licensing rights, shares	379,474
Net loss			(13,779)	(13,779)
Balance at Jun. 30, 2020	$ 21	84,977	(77,967)	7,031
Balance, shares at Jun. 30, 2020	20,956,033
Balance at Mar. 31, 2020	$ 21	83,836	(73,237)	10,620
Balance, shares at Mar. 31, 2020	20,761,960
Stock-based compensation		714		714
Stock-based compensation, shares	15,190
Stock option exercises		66		66
Stock option exercises, shares	64,878
Employee stock purchase plan		64		64
Employee stock purchase plan, shares	14,005
Proceeds from sales of common stock, net of offering costs		297		297
Proceeds from sales of common stock, net of offering costs, shares	100,000
Net loss			(4,730)	(4,730)
Balance at Jun. 30, 2020	$ 21	$ 84,977	$ (77,967)	$ 7,031
Balance, shares at Jun. 30, 2020	20,956,033

Condensed Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Cash flows from operating activities
Net loss	$ (13,779)	$ (10,659)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation	1,079	850
Common stock issued for product candidate licensing rights	1,264
Depreciation and amortization	326	178
Debt discount amortization	50
Changes in operating assets and liabilities:
Accounts receivable	473
Inventory	(1,329)
Prepaid expenses and other assets	1,251	(1,052)
Accounts payable	1,378	(69)
Accrued liabilities	(783)	(211)
Net cash used in operating activities	(10,070)	(10,963)
Cash used in investing activities
Purchases of property and equipment	(4)	(1,030)
Cash flows from financing activities
Proceeds from sales of common stock, net of offering costs	7,756
Proceeds from PPP loan	361
Proceeds from employee stock purchase plan and stock option exercises	161	205
Net cash provided by financing activities	8,278	205
Change in cash and cash equivalents	(1,796)	(11,788)
Cash and cash equivalents at beginning of period	12,066	26,735
Cash and cash equivalents at end of period	10,270	14,947
Supplemental disclosures of cash flow information
Cash paid for interest	358
Cash paid for income taxes

Summary of Significant Accounting Policies

6 Months Ended

Jun. 30, 2020

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

Note 3 — Summary of Significant Accounting Policies

Basis of Presentation

The Company has prepared the accompanying financial statements in accordance with accounting principles generally accepted in the United States of America (“GAAP”).

Unaudited Interim Financial Information

The accompanying interim condensed financial statements are unaudited and have been prepared on the same basis as the audited financial statements and, in the opinion of management, reflect all adjustments necessary for the fair presentation of the Company’s financial position as of June 30, 2020 and the results of its operations and its cash flows for the periods ended June 30, 2020 and 2019. The financial data and other information disclosed in these notes related to the three and six-month periods ended June 30, 2020 and 2019 are also unaudited. The results for the six-month period ended June 30, 2020 are not necessarily indicative of results to be expected for the year ending December 31, 2020, any other interim periods or any future year or period.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed financial statements and the reported amounts of revenue and expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed financial statements include, but are not limited to, provisions for uncollectible receivables and sales returns, valuation of inventories, useful lives of assets and the impairment of property and equipment, the accrual of research and development expenses and the valuation of common stock, stock options and warrants. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates or assumptions.

Intangible Assets

The Company capitalizes payments it makes for licensed products when the payment is based on FDA approval for the product and the cost is recoverable based on expected future cash flows from the product. The cost is amortized on a straight-line basis over the estimated useful life of the product commencing on the approval date in accordance with Accounting Standards Codification (“ASC”) 350 — Intangibles - Goodwill and Other. To date, a $750 payment related to the approval of the Company’s Biorphen product has been capitalized and that cost is being amortized over five years.

Impairment of Long-Lived Assets

Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized in the Company’s statements of operations for the amount by which the carrying amount of the asset exceeds the fair value of the asset. No impairment has been recognized since the Company’s inception in 2017.

Revenue Recognition for Contracts with Customers

The Company intends to generate its future revenues from direct sales of its approved Biorphen product and other of its products which are in development. In addition, the Company anticipates it will receive revenues from product licensing agreements for which it has contracted for milestone payments and royalties from products it has developed or for which it has acquired the rights to a product developed by a third party.

The Company accounts for contracts with its customers in accordance with ASC 606 — Revenue from Contracts with Customers. ASC 606 applies to all contracts with customers, except for contracts that are within the scope of other standards. Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation.

At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. Arrangements that include rights to additional goods or services that are exercisable at a customer’s discretion are generally considered options. The Company assesses whether these options provide a material right to the customer and, if so, they are considered performance obligations. The exercise of a material right is accounted for as a contract modification for accounting purposes.

The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied at a point in time or over time, and if over time this is based on the use of an output or input method. Any amounts received prior to revenue recognition will be recorded as deferred revenue. Amounts expected to be recognized as revenue within the twelve months following the balance sheet date will be classified as current portion of deferred revenue in the Company’s balance sheets. Amounts not expected to be recognized as revenue within the twelve months following the balance sheet date are classified as long-term deferred revenue, net of current portion.

Milestone Payments – If a commercial contract arrangement includes development and regulatory milestone payments, the Company will evaluate whether the milestone conditions have been achieved and if it is probable that a significant revenue reversal would not occur before recognizing the associated revenue. Milestone payments that are not within the Company’s control or the licensee’s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received.

Royalties – For arrangements that include sales-based royalties, including milestone payments based on a level of sales, which are the result of a customer-vendor relationship and for which the license is deemed to be the predominant item to which the royalties relate, the Company will recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied. To date, the Company has not recognized any royalty revenue resulting from any of its licensing arrangements.

Significant Financing Component – In determining the transaction price, the Company will adjust consideration for the effects of the time value of money if the expected period between payment by the licensees and the transfer of the promised goods or services to the licensees will be more than one year.

The Company sells Biorphen in the U.S. to wholesale pharmaceutical distributors, which then sell the product to hospitals and other end-user customers. Sales to wholesalers are made pursuant to purchase orders subject to the terms of a master agreement, and delivery of individual shipments of Biorphen represent performance obligations under each purchase order. The Company uses a third-party logistics (“3PL”) vendor to process and fulfill orders and has concluded it is the principal in the sales to wholesalers because it controls access to the 3PL vendor services rendered and directs the 3PL vendor activities. The Company has no significant obligations to wholesalers to generate pull-through sales.

Selling prices initially billed to wholesalers are subject to discounts for prompt payment and subsequent chargebacks when the wholesalers sell Biorphen at negotiated discounted prices to members of certain group purchasing organizations (“GPOs”) and government programs. In addition, the Company pays fees to wholesalers for their distribution services, inventory reporting and chargeback processing. The Company pays GPO fees for administrative services and for access to GPO members and concluded the benefits received in exchange for these fees are not distinct from its sales of Biorphen, and accordingly it applies these amounts to reduce revenues. Wholesalers also have rights to return unsold product nearing or past the expiration date. Because of the shelf life of Biorphen and the Company’s lengthy return period, there may be a significant period of time between when the product is shipped and when the Company issues credits on returned product.

The Company estimates the transaction price when it receives each purchase order, taking into account the expected reductions of the selling price initially billed to the wholesaler arising from all of the above factors. The Company has developed estimates for future returns and chargebacks of Biorphen and the impact of the other discounts and fees it pays. When estimating these adjustments to the transaction price, the Company reduces it sufficiently to be able to assert that it is probable that there will be no significant reversal of revenue when the ultimate adjustment amounts are known.

The Company recognizes revenue from Biorphen product sales and related cost of sales upon product delivery to the wholesaler location. At that time, the wholesalers take control of the product as they take title, bear the risk of loss, and have an enforceable obligation to pay the Company. They also have the ability to direct sales of product to their customers on terms and at prices they negotiate. Although wholesalers have product return rights, the Company does not believe they have a significant incentive to return the product.

Upon recognition of revenue from product sales of Biorphen, the estimated amounts of credit for product returns, chargebacks, distribution fees, prompt payment discounts, and GPO fees are included in sales reserves, accrued liabilities and net of accounts receivable. The Company monitors actual product returns, chargebacks, discounts and fees subsequent to the sale. If these amounts end up differing from the Company’s estimates, it will make adjustments to these allowances, which are applied to increase or reduce product sales revenue and earnings in the period of adjustment.

In addition, the Company anticipates it will receive revenues from product licensing agreements where it has contracted for milestone payments and royalties from products it has developed or for which it has acquired the rights to a product developed by a third party.

Cost of Product Sales

Cost of product sales consists of the profit-sharing fees with the Company’s product licensing and development partners, the purchase costs for finished products from third-party manufacturers and freight and handling/storage costs from the Company’s 3PL logistics service provider. The cost of sales for profit-sharing fees and costs for purchased finished products and the associated inbound freight expense is recorded when the associated product sale revenue is recognized in accordance with the terms of shipment to customers while outbound freight and handling/storage fees charged by the 3PL service provider are expensed as they are incurred.

Research and Development Expenses

Research and development (“R&D”) expenses include both internal R&D activities and external contracted services. Internal R&D activity expenses include salaries, benefits and stock-based compensation and other costs to support the Company’s R&D operations. External contracted services include product development efforts including certain product licensor milestone payments, clinical trial activities, manufacturing and control-related activities and regulatory costs. R&D expenses are charged to operations as incurred. The Company reviews and accrues R&D expenses based on services performed and relies upon estimates of those costs applicable to the stage of completion of each project. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company’s estimates.

Upfront payments and milestone payments made for the licensing of technology on products which are not yet approved by the FDA are expensed as R&D in the period in which they are incurred. Milestone payments for FDA-approved products are capitalized and amortized over the expected economic life of the product. Nonrefundable advance payments for goods or services to be received in the future for use in R&D activities are recorded as prepaid expenses and are expensed as the related goods are delivered or the services are performed.

Earnings (Loss) Per Share

Basic net loss per common share is computed by dividing net loss for the period by the weighted average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing the net loss for the period by the weighted average number of common and common equivalent shares, such as unvested restricted stock awards (“RSA”), restricted stock units (“RSU’”), stock options and warrants, outstanding during the period. Common stock equivalents (using the treasury stock and “if converted” method) from stock options, unvested RSAs and RSUs, and warrants at June 30, 2020 and 2019 were 3,307,335 and 3,460,950, respectively, and are excluded from the calculation of diluted net loss per share because the effect is anti-dilutive. Included in the basic and diluted net loss per share calculation are RSUs awarded to directors that have vested, but the issuance and delivery of the common shares are deferred until the director retires from service as a director.

Stock-Based Compensation

The Company accounts for stock-based compensation under the provisions of ASC 718 Compensation — Stock Compensation. The guidance under ASC 718 requires companies to estimate the fair value of the stock-based compensation awards on the date of grant and record expense over the related service periods, which are generally the vesting period of the equity awards. The Company estimates the fair value of stock-based option awards using the Black-Scholes-Merton option-pricing model (“BSM”). The BSM requires the input of subjective assumptions, including the expected stock price volatility, the calculation of expected term, forfeitures and the fair value of the underlying common stock on the date of grant, among other inputs. The risk-free interest rate was determined from the implied yields for zero-coupon U.S. government issues with a remaining term approximating the expected life of the options or warrants. Dividends on common stock are assumed to be zero for the BSM valuation of the stock options. The expected term of stock options granted is based on vesting periods and the contractual life of the options. Expected volatilities are based on comparable companies’ historical volatility along with a limited weighting included for the Company’s own volatility subsequent to its IPO, which management believes represents the most accurate basis for estimating expected future volatility under the current conditions. The Company accounts for forfeitures as they occur. Since the IPO in November 2018, the Company has used the closing common stock price on the date of grant for the fair value of the common stock.

Fair Value Measurements

We measure certain of our assets and liabilities at fair value. Fair value represents the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value accounting requires characterization of the inputs used to measure fair value into a three-level fair value hierarchy as follows:

Level 1 — Inputs based on quoted prices in active markets for identical assets or liabilities. An active market is a market in which transactions occur with sufficient frequency and volume to provide pricing information on an ongoing basis.

Level 2 — Observable inputs that reflect the assumptions market participants would use in pricing the asset or liability developed based on market data obtained from sources independent from the entity.

Level 3 — Unobservable inputs that reflect the entity’s own assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available.

Fair value measurements are classified based on the lowest level of input that is significant to the measurement. The Company’s assessment of the significance of a particular input to the fair value measurement requires judgment, which may affect the valuation of the assets and liabilities and their placement within the fair value hierarchy levels. The determination of the fair values stated below take into account the market for the Company’s financials, assets and liabilities, the associated credit risk and other factors as required. The Company considers active markets as those in which transactions for the assets or liabilities occur in sufficient frequency and volume to provide pricing information on an ongoing basis.

The Company’s financial instruments included cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities, PPP loan and long-term debt obligation. The carrying amounts of these financial instruments, except for the PPP loan and long-term debt obligation, approximate their fair values due to the short-term maturities of these instruments. Based on borrowing rates currently available to the Company, the carrying value of the PPP loan and long-term debt obligation approximate their fair values.

Impact of New Accounting Pronouncements

In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820). The new guidance removes, modifies, and adds to certain disclosure requirements on fair value measurements in Topic 820, Fair Value Measurement. The Company adopted the new guidance on January 1, 2020 which did not have a material impact on its financial position or results of operations.

In December 2019, the FASB issued ASU 2019-12, Simplifying the Accounting for Income Taxes. The new guidance removes certain exceptions to the general principles of ASC 740 in order to simplify the complexities of its application. These changes include eliminations to the exceptions for intraperiod tax allocation, recognizing deferred tax liabilities related to outside basis differences, and year-to-date losses in interim periods, among others. The Company adopted the new guidance on January 1, 2020 which did not have a material impact on its financial position or results of operations.

Share-Based Payment Awards

6 Months Ended

Jun. 30, 2020

Share-based Payment Arrangement [Abstract]

Share-Based Payment Awards

Note 8 — Share-Based Payment Awards

The Company’s board of directors and stockholders approved the Eton Pharmaceuticals, Inc. 2017 Equity Incentive Plan in May 2017 (the “2017 Plan”), which authorized the issuance of up to 5,000,000 shares of the Company’s common stock. In conjunction with the Company’s IPO in November 2018, the Company’s stockholders and board of directors approved the 2018 Equity Incentive Plan (the “2018 Plan”) which succeeded the 2017 Plan. The Company has granted RSAs, stock options and RSUs for its common stock under the 2018 Plan as detailed below. There were 510,746 shares available for future issuance under the 2018 Plan as of June 30, 2020.

Shares that are expired, terminated, surrendered or canceled without having been fully exercised will be available for future awards under the 2018 Plan. In addition, the 2018 Plan provides that commencing January 1, 2019 and through January 1, 2028, the share reserve will be increased annually by 4% of the total number of shares of common stock outstanding as of the preceding December 31, subject to a reduction at the discretion of the Company’s board of directors. The exercise price for stock options granted is not less than the fair value of common stock as determined by the board of directors as of the date of grant. The Company uses the closing stock price on the date of grant as the exercise price.

During the third quarter of 2017, the Company issued 25,000 RSU’s to each of its four outside directors (100,000 total share units). The RSU’s issued to the outside directors were 100% vested at June 30, 2018. The associated 100,000 shares of the Company’s common stock will not be issued until the individual director retires from service from the Company’s board of directors. The Company has not issued any additional RSU’s.

To date, all stock options issued have been non-qualified stock options, and the exercise prices were set at the fair value for the shares at the dates of grant. Options typically have a ten-year life, except for options to purchase 50,000 shares of the Company’s common stock granted to product consultants that expire within five years if the Company is not able to file certain product submissions to the FDA prior to the five-year expiration date. Furthermore, these option awards to the Company’s product consultants do not vest unless certain product submissions are made to the FDA, and accordingly, the Company has not recorded any expense for these contingently vesting option awards to its product consultants.

For the three months ended June 30, 2020 and 2019, the Company’s total stock-based compensation expense was $714 and $505, respectively. Of these amounts, $651 and $421 was recorded in general and administrative expenses, respectively, and $63 and $84 was recorded in research and development expenses, respectively.

For the six months ended June 30, 2020 and 2019, the Company’s total stock-based compensation expense was $1,079 and $850, respectively. Of these amounts, $976 and $690 was recorded in general and administrative expenses, respectively, and $103 and $160 was recorded in research and development expenses, respectively.

A summary of stock option activity is as follows:

	Shares			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Yrs)		Aggregate Intrinsic Value
Options outstanding as of December 31, 2019		1,829,878		$	4.01		8.1	$	6,014
Issued		1,302,000		$	3.65
Exercised		(69,878	)	$	1.39
Forfeited/Cancelled		(225,000	)	$	5.86
Options outstanding as of June 30, 2020		2,837,000		$	3.76		8.6	$	5,949
Options exercisable at June 30, 2020		895,521		$	3.65		7.7	$	2,177
Options vested and expected to vest at June 30, 2020		2,787,000		$	3.81		8.6	$	5,746

The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company’s common stock for those stock options that had strike prices lower than the fair value of the Company’s common stock.

The assumptions used to calculate the fair value of options granted during the six months ended June 30, 2020 under the BSM were as follows:

Expected dividends		—	%
Expected volatility		95	%
Risk-free interest rate		0.4 - 0.7	%
Expected term		5.3 – 6.3 years
Weighted average fair value	$	2.76

Expected Term — The Company has opted to use the “simplified method” for estimating the expected term of options granted to employees and directors, whereby the expected term equals the arithmetic average of the vesting term and the original contractual term of the option (generally ten years). The expected term of options granted to non-employees equals the contractual life of the options.

Expected Volatility — Due to the Company’s limited operating history and a lack of Company-specific historical and implied volatility data, the Company has based its estimate of expected volatility on the historical volatility of a group of similar companies that are publicly traded. The Company has continued this methodology plus given some limited weighting to its own volatility in the periods subsequent to its November 2018 IPO. The historical volatility data was computed using the daily closing prices for the selected companies’ shares during the equivalent period of the calculated expected term of the stock-based awards.

Risk-Free Interest Rate — The risk-free rate assumption is based on the U.S. Treasury instruments with maturities similar to the expected term of the Company’s stock options.

Expected Dividend — The Company has not issued any dividends in its history and does not expect to issue dividends over the life of the options and therefore has estimated the dividend yield to be zero.

Fair Value of Common Stock —The Company uses the closing stock price on the date of grant for the fair value of the common stock.

As of June 30, 2020, there was a total of $5,160 of unrecognized compensation costs related to non-vested stock option and restricted awards. In the six-month period ended June 30, 2020, there were four stock option exercises which totaled 69,878 shares at an average exercise price of $1.39 per share with an intrinsic value of $139. There were four stock option exercises for 90,000 shares during the six months ended June 30, 2019 at an average exercise price of $0.86 per share with an intrinsic value of $599.

In December 2018, the Company’s board of directors approved and adopted an initial offering of the Company’s common stock under the Company’s 2018 ESPP. The Company’s ESPP provides for an initial reserve of 150,000 shares and this reserve is automatically increased on January 1 of each year by the lesser of 1% of the outstanding common shares at December 31 of the preceding year or 150,000 shares, subject to reduction at the discretion of the Company’s board of directors. As of June 30, 2020, there were 391,110 shares available for issuance under the ESPP.

The annual offerings consist of two stock purchase periods, with the first purchase period ending in June and the second purchase period ending in December. The terms of the ESPP permit employees of the Company to use payroll deductions to purchase stock at a price per share that is at least the lesser of (1) 85% of the fair market value of a share of common stock on the first date of an offering or (2) 85% of the fair market value of a share of common stock on the date of purchase. After the initial offering period ended, subsequent twelve-month offering periods automatically commence over the term of the ESPP on the day that immediately follows the conclusion of the preceding offering, each consisting of two purchase periods approximately six months in duration.

For the first six months of 2020 and 2019 there were 14,005 and 23,083 share issuances under the ESPP. The weighted average grant date fair value of share awards in the first six months of 2020 and 2019 was $2.43 and $2.57, respectively. Employees contributed $66 and $141 via payroll deductions during the six months ended June 30, 2020 and 2019, respectively. The Company recorded an expense of $33 and $75 related to the ESPP in the six-month periods ended June 30, 2020 and 2019, respectively. As of June 30, 2020 and December 31, 2019, the accompanying condensed balance sheets include $9 and $16, respectively, in accrued liabilities for remaining employee ESPP contributions.

Related Party Transactions

6 Months Ended

Jun. 30, 2020

Related Party Transactions

Note 9 — Related Party Transactions

Harrow

Harrow was issued 3,500,000 shares of the Company’s common stock at the formation of the Company at the $0.001 par value per share price as the paid-in-capital contribution from Harrow. The Company and Harrow signed licensing agreements for two products developed by Harrow whereby Harrow assigned the product rights to the Company. In July 2018, the Company determined that one of the products was not viable for its portfolio of product opportunities and cancelled the licensing agreement and the product rights were returned to Harrow.

As part of the early start-up for the Company’s pharmaceutical business in 2017, key executives at Harrow received a total of 1,500,000 shares of restricted common stock in the Company for consulting services, and certain Harrow managers also received stock options to purchase a total of 130,000 shares of common stock from the Company (20,000 of these options were forfeited in 2018). The restricted stock and stock options vested in full on April 30, 2018.

Additionally, the Chief Executive Officer of Harrow is a member of the Company’s board of directors.

Chief Executive Officer

The Company’s CEO has a partial interest in several companies that the Company is working with for product development and potential marketing if the products are approved by the FDA as detailed below.

The Company acquired the exclusive rights to sell the EM-100 product in the United States pursuant to a sales and marketing agreement (the “Eyemax Agreement”) dated August 11, 2017 between the Company and Eyemax LLC (“Eyemax”), an entity affiliated with the Company’s CEO. The Company also held a right of first refusal to obtain the exclusive license rights for geographic areas outside of the United States. Pursuant to the Eyemax Agreement, the Company is responsible for all costs of testing and FDA approval of the product, other than the FDA filing fee which will be paid by Eyemax. The Company was also responsible for commercializing the product in the United States at its expense. The Company paid Eyemax $250 upon execution of the Eyemax Agreement, which was recorded as a component of R&D expense. Under the terms of the original agreement, the Company would pay Eyemax $250 upon FDA approval and $500 upon the first commercial sale of the product and pay Eyemax a royalty of 10% on the net sales of all products. The Eyemax Agreement was for an initial term of 10 years from the date of the Eyemax Agreement, subject to successive two-year renewals unless the Company elected to terminate the Eyemax Agreement. There were no amounts due under the terms of the Eyemax Agreement as of June 30, 2020 or December 31, 2019.

On February 18, 2019, The Company entered into an Amended and Restated Agreement with Eyemax amending the Sales Agreement (the “Amended Agreement”). Pursuant to the Amended Agreement, Eyemax sold the Company all of its right, title and interest in EM-100, including any such product that incorporates or utilizes Eyemax’s intellectual property rights. Under the Amended Agreement, the Company assumed certain liabilities of Eyemax under its Exclusive Development & Supply Agreement with Excelvision SAS dated as of July 11, 2013, as amended (the “Excelvision Agreement”), with respect to certain territories and arising during certain time periods. Pursuant to the Amended Agreement, the Company remains obligated to pay Eyemax two milestones payments: (i) one milestone payment for $250 upon regulatory approval in the territory by the FDA of the first single agent product and (ii) one milestone payment for $500 following the first commercial sale of the first single agent product in the territory. Following payment of the milestones, the Company is entitled to retain all of the non-royalty transaction revenues and royalties up to $2,000 (the “Recovery Amount”). After the Company has retained the full Recovery Amount, it is entitled to retain half of all royalty and non-royalty transaction revenue. The Amended Agreement also contains customary representations, warranties, covenants and indemnities by the parties. The EM-100 asset and its associated product rights were sold to Bausch on February 18, 2019 and future potential royalties of twelve percent of net sales of Bausch sales of EM-100, pending an FDA approval for EM-100, will be split between Eyemax and the Company. The royalty from Bausch is subject to reduction if a competitive product with the same active pharmaceutical ingredient is launched in the U.S. or if the EM-100 U.S market share falls below a specified target percentage. There were no amounts due under the terms of the Amended Agreement as of June 30, 2020 or December 31, 2019. The FDA revised the target action date for EM-100 from August 10, 2020 to September 15, 2020.

The Company acquired the DS-200 product and all related intellectual property and government approvals pursuant to an asset purchase agreement (the “Selenix Agreement”) dated June 23, 2017 between the Company and Selenix LLC (“Selenix”), an entity affiliated with the Company’s CEO. Pursuant to the Selenix Agreement, the Company paid Selenix $1,500 at signing, which was recorded as a component of R&D expense and paid $1,500 in April 2019 upon submission of an NDA on March 13, 2019 which was reflected as a component of R&D expense in 2019. The Company will pay $1,000 upon FDA approval of the DS-200 product. The Company has also agreed to pay Selenix 50% of the net profit from the sale of the product for the first 10 years following the date of the Selenix Agreement. There were no amounts due under the terms of the Selenix Agreement as of June 30, 2020 or December 31, 2019.

Commitments and Contingencies

6 Months Ended

Jun. 30, 2020

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

Note 11 — Commitments and Contingencies

Legal

The Company is subject to legal proceedings and claims that may arise in the ordinary course of business. The Company is not aware of any pending or threatened litigation matters at this time that may have a material impact on the operations of the Company.

On May 7, 2020, the Company announced that it has been confirmed as the first filer of a patent challenge against Exela Pharma Science’s Elcys product (cysteine hydrochloride injection).

License and product development agreements

The Company has entered into various agreements in addition to those discussed above which are described below.

The Company acquired the exclusive rights to sell the DS-300 product in the United States pursuant to a sales and marketing agreement dated November 17, 2017 with an unaffiliated third party (the “Sales Agreement”). Pursuant to the Sales Agreement, the licensor is responsible for obtaining FDA approval, at its expense, and the Company is responsible for commercializing the product in the United States at its expense. The Company will be responsible for Paragraph IV litigation management and expense for the product and will be entitled to 62.5% of the net profit from the sale of the product. The initial term is for the first 10 years following the first commercial sale of the product.

The Company acquired the exclusive license to develop, manufacture and sell ET-103 in the United States pursuant to an Exclusive License and Supply Agreement dated August 3, 2018 between the Company and Liqmeds Worldwide Limited (“LMW”), an unaffiliated entity. Pursuant to the agreement, the Company will be responsible for, and will own, all regulatory filings and approvals at its expense, provided that it shall have the right to recoup 35% of any regulatory filing fees from the initial profits from the sale of ET-103 and, provided further, the licensor shall be responsible for any bioequivalence study and shall be responsible for 60% of the costs of such study. An affiliate of the licensor shall manufacture the ET-103 and sell it to the Company at its cost. The Company paid the licensor $350 upon execution of the agreement and will pay the licensor $1,500 upon the FDA’s acceptance of an NDA for review, $1,000 upon FDA approval, $1,500 upon issuance of patent covering ET-103 listed in the FDA’s Orange Book and $500 in the event of product sales in excess of $10,000 in any calendar year. In addition, the Company is required to pay the licensor 35% of the net profit from product sales. The license agreement is for an initial term of 10 years from the date of the first commercial sale of the product, subject to two-year renewals unless either party elects to terminate no less than 12 months prior to the then current term. The agreement also contains customary representations, warranties, covenants and indemnities by the parties.

On January 23, 2019, the Company entered into a Licensing and Supply Agreement (the “Agreement”) with LMW for ET-104 oral liquid, a development stage product candidate (“ET-104”). Pursuant to the terms of the Agreement, the Company will be responsible for regulatory and marketing activities. LMW will be responsible for development and manufacturing of ET-104. The Company paid the licensor $350 upon execution of the Agreement and an additional $350 after receiving successful bioequivalence study results, and will pay $325 upon the FDA’s acceptance of an NDA for review, $325 upon FDA approval of the NDA, $650 upon issuance of patent covering ET-104 listed in the FDA’s Orange Book and $500 in the event that product sales in excess of $10,000 are achieved within a calendar year. In addition, the Company is required to pay the licensor 35% of the net profit from product sales. The Agreement is for an initial term of 10 years from the date of the first commercial sale of the product. The Company will retain sole ownership of the NDA after expiration of the Agreement.

On February 8, 2019, the Company entered into an Exclusive Licensing and Supply Agreement (the “ET-202 License Agreement”) with Sintetica SA (“Sintetica”) for marketing rights in the United States to Biorphen® which is used for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia. The product was submitted to the FDA for review and received FDA approval on October 21, 2019. Pursuant to the terms of the ET-202 License Agreement, the Company is responsible for marketing activities and Sintetica is responsible for development, manufacturing, and regulatory activities for the product. In 2019, the Company paid Sintetica a licensing payment of $2,000 upon execution of the ET-202 License Agreement and paid $750 upon the commencement of commercial product shipments. Sintetica supplies Biorphen to the Company at its direct costs and the Company retains 5% of net sales as a marketing fee. Sintetica is entitled to receive the first $500 of product profits. All additional profit will be split 50% to the Company and 50% to Sintetica. The ET-202 License Agreement has a ten-year term commencing on November 26, 2019.

On February 8, 2019, the Company also entered into an Exclusive Licensing and Supply Agreement (the “ET-203 License Agreement”) with Sintetica for marketing rights in the United States to ET-203, an injectable product candidate for use in the hospital setting. Pursuant to the terms of the ET-203 License Agreement, the Company will be responsible for marketing activities and Sintetica will be responsible for development, manufacturing, and regulatory activities related to obtaining regulatory approval. The Company paid Sintetica a licensing payment of $1,000 upon execution of the ET-203 License Agreement and will pay $750 upon FDA approval and the commercial sale of the product candidate. Upon approval, Sintetica will supply ET-203 to the Company at its direct costs. The Company will retain 5% of net sales as a marketing fee. Sintetica will be entitled to receive the first $500 of product profits. All additional profit will be split 50% to the Company and 50% to Sintetica. The ET-203 License Agreement has a ten-year term from first commercial sale of product.

On June 12, 2019, the Company entered into an Exclusive Licensing and Supply Agreement (the “ET-105 License Agreement”) with Aucta Pharmaceuticals, Inc. (“Aucta”) for marketing rights in the United States to ET-105, a product candidate for use as an adjunct therapy for partial seizures, primary generalized tonic-clonic seizures, and generalized seizures of Lennox-Gastaut syndrome in patients two years of age and older. Pursuant to the terms of the ET-105 License Agreement, the Company will be responsible for marketing activities and Aucta will be responsible for development, manufacturing, and regulatory activities related to obtaining regulatory approval. The Company paid Aucta a licensing payment of $2,000 in August 2019 upon receiving an acceptance for review letter from the FDA and will pay $2,000 upon FDA approval and commercial sales of the product candidate and another $1,000 upon issuance of an Orange-book listed patent. Aucta will receive a 15% royalty on net sales and will be entitled to receive milestone payments of up to $18,000 based on commercial success of the product, including:

	●	$1,000 when net sales exceed $10 million in a calendar year
	●	$2,000 when net sales exceed $20 million in a calendar year
	●	$5,000 when net sales exceed $50 million in a calendar year
	●	$10,000 when net sales exceed $100 million in a calendar year

On March 27, 2020, the Company entered into an Exclusive Licensing and Supply Agreement (the “Alkindi License Agreement”) with Diurnal for marketing Alkindi Sprinkle in the United States. Alkindi Sprinkle’s New Drug Application (NDA) is currently under review with the FDA for approval as a replacement therapy for pediatric adrenal insufficiency (AI), including congenital adrenal hyperplasia (CAH) in patients from birth to less than 17 years of age. The application has been assigned a Prescription Drug User Fee Act (PDUFA) date of September 29, 2020.

For the initial licensing milestone fee, the Company paid Diurnal $3,500 in cash and issued 379,474 shares of its common stock to Diurnal which was valued at $1,264 based on the Company’s closing stock price of $3.33 on March 26, 2020 (see Note 6). The total amount of $4,764 was recorded as a component of research and development expense in the Company’s condensed statement of operations for the six-month period ended June 30, 2020.

Indemnifications

As permitted under Delaware law and in accordance with the Company’s Amended and Restated Bylaws, the Company is required to indemnify its officers and directors for certain events or occurrences while the officer or director is or was serving in such capacity. The Company is also party to indemnification agreements with its directors and officers. The Company believes the fair value of the indemnification rights and agreements is minimal. Accordingly, the Company has not recorded any liabilities for these indemnification rights and agreements as of June 30, 2020 or December 31, 2019.

Summary of Significant Accounting Policies (Policies)	6 Months Ended
Summary of Significant Accounting Policies (Policies)	Jun. 30, 2020
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The Company has prepared the accompanying financial statements in accordance with accounting principles generally accepted in the United States of America (“GAAP”).
Unaudited Interim Financial Information	Unaudited Interim Financial Information The accompanying interim condensed financial statements are unaudited and have been prepared on the same basis as the audited financial statements and, in the opinion of management, reflect all adjustments necessary for the fair presentation of the Company’s financial position as of June 30, 2020 and the results of its operations and its cash flows for the periods ended June 30, 2020 and 2019. The financial data and other information disclosed in these notes related to the three and six-month periods ended June 30, 2020 and 2019 are also unaudited. The results for the six-month period ended June 30, 2020 are not necessarily indicative of results to be expected for the year ending December 31, 2020, any other interim periods or any future year or period.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed financial statements and the reported amounts of revenue and expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed financial statements include, but are not limited to, provisions for uncollectible receivables and sales returns, valuation of inventories, useful lives of assets and the impairment of property and equipment, the accrual of research and development expenses and the valuation of common stock, stock options and warrants. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates or assumptions.
Intangible Assets	Intangible Assets The Company capitalizes payments it makes for licensed products when the payment is based on FDA approval for the product and the cost is recoverable based on expected future cash flows from the product. The cost is amortized on a straight-line basis over the estimated useful life of the product commencing on the approval date in accordance with Accounting Standards Codification (“ASC”) 350 — Intangibles - Goodwill and Other. To date, a $750 payment related to the approval of the Company’s Biorphen product has been capitalized and that cost is being amortized over five years.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized in the Company’s statements of operations for the amount by which the carrying amount of the asset exceeds the fair value of the asset. No impairment has been recognized since the Company’s inception in 2017.
Revenue Recognition for Contracts with Customers	Revenue Recognition for Contracts with Customers The Company intends to generate its future revenues from direct sales of its approved Biorphen product and other of its products which are in development. In addition, the Company anticipates it will receive revenues from product licensing agreements for which it has contracted for milestone payments and royalties from products it has developed or for which it has acquired the rights to a product developed by a third party. The Company accounts for contracts with its customers in accordance with ASC 606 — Revenue from Contracts with Customers. ASC 606 applies to all contracts with customers, except for contracts that are within the scope of other standards. Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. Arrangements that include rights to additional goods or services that are exercisable at a customer’s discretion are generally considered options. The Company assesses whether these options provide a material right to the customer and, if so, they are considered performance obligations. The exercise of a material right is accounted for as a contract modification for accounting purposes. The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied at a point in time or over time, and if over time this is based on the use of an output or input method. Any amounts received prior to revenue recognition will be recorded as deferred revenue. Amounts expected to be recognized as revenue within the twelve months following the balance sheet date will be classified as current portion of deferred revenue in the Company’s balance sheets. Amounts not expected to be recognized as revenue within the twelve months following the balance sheet date are classified as long-term deferred revenue, net of current portion. Milestone Payments – If a commercial contract arrangement includes development and regulatory milestone payments, the Company will evaluate whether the milestone conditions have been achieved and if it is probable that a significant revenue reversal would not occur before recognizing the associated revenue. Milestone payments that are not within the Company’s control or the licensee’s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. Royalties – For arrangements that include sales-based royalties, including milestone payments based on a level of sales, which are the result of a customer-vendor relationship and for which the license is deemed to be the predominant item to which the royalties relate, the Company will recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied. To date, the Company has not recognized any royalty revenue resulting from any of its licensing arrangements. Significant Financing Component – In determining the transaction price, the Company will adjust consideration for the effects of the time value of money if the expected period between payment by the licensees and the transfer of the promised goods or services to the licensees will be more than one year. The Company sells Biorphen in the U.S. to wholesale pharmaceutical distributors, which then sell the product to hospitals and other end-user customers. Sales to wholesalers are made pursuant to purchase orders subject to the terms of a master agreement, and delivery of individual shipments of Biorphen represent performance obligations under each purchase order. The Company uses a third-party logistics (“3PL”) vendor to process and fulfill orders and has concluded it is the principal in the sales to wholesalers because it controls access to the 3PL vendor services rendered and directs the 3PL vendor activities. The Company has no significant obligations to wholesalers to generate pull-through sales. Selling prices initially billed to wholesalers are subject to discounts for prompt payment and subsequent chargebacks when the wholesalers sell Biorphen at negotiated discounted prices to members of certain group purchasing organizations (“GPOs”) and government programs. In addition, the Company pays fees to wholesalers for their distribution services, inventory reporting and chargeback processing. The Company pays GPO fees for administrative services and for access to GPO members and concluded the benefits received in exchange for these fees are not distinct from its sales of Biorphen, and accordingly it applies these amounts to reduce revenues. Wholesalers also have rights to return unsold product nearing or past the expiration date. Because of the shelf life of Biorphen and the Company’s lengthy return period, there may be a significant period of time between when the product is shipped and when the Company issues credits on returned product. The Company estimates the transaction price when it receives each purchase order, taking into account the expected reductions of the selling price initially billed to the wholesaler arising from all of the above factors. The Company has developed estimates for future returns and chargebacks of Biorphen and the impact of the other discounts and fees it pays. When estimating these adjustments to the transaction price, the Company reduces it sufficiently to be able to assert that it is probable that there will be no significant reversal of revenue when the ultimate adjustment amounts are known. The Company recognizes revenue from Biorphen product sales and related cost of sales upon product delivery to the wholesaler location. At that time, the wholesalers take control of the product as they take title, bear the risk of loss, and have an enforceable obligation to pay the Company. They also have the ability to direct sales of product to their customers on terms and at prices they negotiate. Although wholesalers have product return rights, the Company does not believe they have a significant incentive to return the product. Upon recognition of revenue from product sales of Biorphen, the estimated amounts of credit for product returns, chargebacks, distribution fees, prompt payment discounts, and GPO fees are included in sales reserves, accrued liabilities and net of accounts receivable. The Company monitors actual product returns, chargebacks, discounts and fees subsequent to the sale. If these amounts end up differing from the Company’s estimates, it will make adjustments to these allowances, which are applied to increase or reduce product sales revenue and earnings in the period of adjustment. In addition, the Company anticipates it will receive revenues from product licensing agreements where it has contracted for milestone payments and royalties from products it has developed or for which it has acquired the rights to a product developed by a third party.
Cost of Product Sales	Cost of Product Sales Cost of product sales consists of the profit-sharing fees with the Company’s product licensing and development partners, the purchase costs for finished products from third-party manufacturers and freight and handling/storage costs from the Company’s 3PL logistics service provider. The cost of sales for profit-sharing fees and costs for purchased finished products and the associated inbound freight expense is recorded when the associated product sale revenue is recognized in accordance with the terms of shipment to customers while outbound freight and handling/storage fees charged by the 3PL service provider are expensed as they are incurred.
Research and Development Expenses	Research and Development Expenses Research and development (“R&D”) expenses include both internal R&D activities and external contracted services. Internal R&D activity expenses include salaries, benefits and stock-based compensation and other costs to support the Company’s R&D operations. External contracted services include product development efforts including certain product licensor milestone payments, clinical trial activities, manufacturing and control-related activities and regulatory costs. R&D expenses are charged to operations as incurred. The Company reviews and accrues R&D expenses based on services performed and relies upon estimates of those costs applicable to the stage of completion of each project. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company’s estimates. Upfront payments and milestone payments made for the licensing of technology on products which are not yet approved by the FDA are expensed as R&D in the period in which they are incurred. Milestone payments for FDA-approved products are capitalized and amortized over the expected economic life of the product. Nonrefundable advance payments for goods or services to be received in the future for use in R&D activities are recorded as prepaid expenses and are expensed as the related goods are delivered or the services are performed.
Earnings (Loss) Per Share	Earnings (Loss) Per Share Basic net loss per common share is computed by dividing net loss for the period by the weighted average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing the net loss for the period by the weighted average number of common and common equivalent shares, such as unvested restricted stock awards (“RSA”), restricted stock units (“RSU’”), stock options and warrants, outstanding during the period. Common stock equivalents (using the treasury stock and “if converted” method) from stock options, unvested RSAs and RSUs, and warrants at June 30, 2020 and 2019 were 3,307,335 and 3,460,950, respectively, and are excluded from the calculation of diluted net loss per share because the effect is anti-dilutive. Included in the basic and diluted net loss per share calculation are RSUs awarded to directors that have vested, but the issuance and delivery of the common shares are deferred until the director retires from service as a director.
Stock-Based Compensation	Stock-Based Compensation The Company accounts for stock-based compensation under the provisions of ASC 718 Compensation — Stock Compensation. The guidance under ASC 718 requires companies to estimate the fair value of the stock-based compensation awards on the date of grant and record expense over the related service periods, which are generally the vesting period of the equity awards. The Company estimates the fair value of stock-based option awards using the Black-Scholes-Merton option-pricing model (“BSM”). The BSM requires the input of subjective assumptions, including the expected stock price volatility, the calculation of expected term, forfeitures and the fair value of the underlying common stock on the date of grant, among other inputs. The risk-free interest rate was determined from the implied yields for zero-coupon U.S. government issues with a remaining term approximating the expected life of the options or warrants. Dividends on common stock are assumed to be zero for the BSM valuation of the stock options. The expected term of stock options granted is based on vesting periods and the contractual life of the options. Expected volatilities are based on comparable companies’ historical volatility along with a limited weighting included for the Company’s own volatility subsequent to its IPO, which management believes represents the most accurate basis for estimating expected future volatility under the current conditions. The Company accounts for forfeitures as they occur. Since the IPO in November 2018, the Company has used the closing common stock price on the date of grant for the fair value of the common stock.
Fair Value Measurements	Fair Value Measurements We measure certain of our assets and liabilities at fair value. Fair value represents the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value accounting requires characterization of the inputs used to measure fair value into a three-level fair value hierarchy as follows: *Level 1* — Inputs based on quoted prices in active markets for identical assets or liabilities. An active market is a market in which transactions occur with sufficient frequency and volume to provide pricing information on an ongoing basis. *Level 2* — Observable inputs that reflect the assumptions market participants would use in pricing the asset or liability developed based on market data obtained from sources independent from the entity. *Level 3* — Unobservable inputs that reflect the entity’s own assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available. Fair value measurements are classified based on the lowest level of input that is significant to the measurement. The Company’s assessment of the significance of a particular input to the fair value measurement requires judgment, which may affect the valuation of the assets and liabilities and their placement within the fair value hierarchy levels. The determination of the fair values stated below take into account the market for the Company’s financials, assets and liabilities, the associated credit risk and other factors as required. The Company considers active markets as those in which transactions for the assets or liabilities occur in sufficient frequency and volume to provide pricing information on an ongoing basis. The Company’s financial instruments included cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities, PPP loan and long-term debt obligation. The carrying amounts of these financial instruments, except for the PPP loan and long-term debt obligation, approximate their fair values due to the short-term maturities of these instruments. Based on borrowing rates currently available to the Company, the carrying value of the PPP loan and long-term debt obligation approximate their fair values.
Impact of New Accounting Pronouncements	Impact of New Accounting Pronouncements In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820). The new guidance removes, modifies, and adds to certain disclosure requirements on fair value measurements in Topic 820, Fair Value Measurement. The Company adopted the new guidance on January 1, 2020 which did not have a material impact on its financial position or results of operations. In December 2019, the FASB issued ASU 2019-12, Simplifying the Accounting for Income Taxes. The new guidance removes certain exceptions to the general principles of ASC 740 in order to simplify the complexities of its application. These changes include eliminations to the exceptions for intraperiod tax allocation, recognizing deferred tax liabilities related to outside basis differences, and year-to-date losses in interim periods, among others. The Company adopted the new guidance on January 1, 2020 which did not have a material impact on its financial position or results of operations.

Property and Equipment - Schedule of Property and Equipment (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Property, Plant and Equipment [Abstract]
Computer hardware and software	$ 174	$ 174
Furniture and fixtures	134	133
Equipment	994	994
Leasehold improvements	155	152
Construction in progress		9
Property and equipment, gross	1,457	1,462
Less: accumulated depreciation	(519)	(345)
Property and equipment, net	$ 938	$ 1,117

Long-Term Debt (Details Narrative) $ / shares in Units, $ in Thousands			6 Months Ended
	May 04, 2020 USD ($)	Nov. 13, 2019 USD ($)	Jun. 30, 2020 USD ($) $ / shares shares	Jun. 30, 2019 USD ($)
Borrowing amount		$ 2,000
Description of borrowing	The loan bears a 1.0% annual interest rate and is payable in monthly installments commencing on November 4, 2020 until paid in full on May 4, 2022.
Warrants issued to purchase common stock \| shares			1,672,335
Warrants exercise price \| $ / shares			$ 3.13
Interest expenses	$ 1		$ 386
Debt discount amortization			50
Accrued interest			$ 63
Loans proceeds under paycheck protection program	$ 361
Interest rate	0.01
Warrant [Member]
Warrants issued to purchase common stock \| shares			51,239
Warrants exercise price \| $ / shares			$ 5.86
Warrants expiration term			7 years
SWK Credit Agreement [Member]
Borrowing amount		5,000
Minimum cash balance to be maintain in each quarter end		$ 3,000
Description of borrowing		On November 13, 2019, the Company entered into a credit agreement (the "SWK Credit Agreement") with SWK Holdings Corporation ("SWK") which provides for up to $10,000 in financing. The Company received proceeds of $5,000 at closing and was able to borrow an additional $5,000 upon the FDA approval of a second product developed by the Company, excluding EM-100. In March 2020, in conjunction with the Company's Alkindi Sprinkle product licensing agreement (see Note 11) and the Company's March 2020 sale of additional shares of its common stock (see Note 6), the Company and SWK amended the SWK Credit Agreement. The amendment provides the Company with the option to immediately draw $2,000 and can borrow an additional $3,000 upon the FDA approval of both its EM-100 product candidate and another one of its other product candidates. The term of the SWK Credit Agreement is for five years and borrowings bear interest at a rate of LIBOR 3-month plus 10.0%, subject to a stated LIBOR floor rate of 2.0%. A 2.0% unused credit limit fee is assessed during the first twelve months after the date of the SWK Credit Agreement and loan fees include a 5.0% exit fee based on the principal amounts drawn which is payable at the end of the term of the SWK Credit Agreement. The Company is required to maintain a minimum cash balance of $3,000, will only pay interest on the debt until May 2022 and then will pay 5.5% of the loan principal balance commencing on May 15, 2022 and then every three months thereafter until November 13, 2024 at which time the remaining principal balance is due. Borrowings under the SWK Credit Agreement are secured by the Company's assets. The SWK Credit Agreement contains customary default provisions and covenants which include limits on additional indebtedness. In March 2020, SWK provided a waiver for the Company to obtain loans with the Small Business Association. The Company is currently in the process of negotiating covenant targets for EBITDA and revenue for the SWK Credit Agreement.
SWK Credit Agreement [Member] \| Unused lines of Credit [Member]
Borrowings bear interest		2.00%
SWK Credit Agreement [Member] \| (LIBOR) Swap Rate [Member]
Borrowings bear interest		10.00%
SWK Credit Agreement [Member] \| Stated LIBOR Floor Rate [Member]
Borrowings bear interest		2.00%
SWK Credit Agreement [Member] \| Maximum [Member]
Borrowing amount		$ 10,000

Long-Term Debt - Schedule of Future Payments of Long Term Debt (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Debt Disclosure [Abstract]
2020	$ 359
2021	607
2022	1,364
2023	1,327
2024	3,991
Total payments	7,648
Less: amount representing interest	(2,648)
Loan payable, gross	5,000
Less: unamortized discount	(413)
Long-term debt, net of unamortized discount	$ 4,587	$ 4,540

Common Stock (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended				3 Months Ended	6 Months Ended
	Jun. 30, 2020	Apr. 30, 2020	Apr. 30, 2020	Mar. 31, 2020	Jun. 30, 2020	Jun. 30, 2020	Dec. 31, 2019
Common stock, shares authorized	50,000,000				50,000,000	50,000,000	50,000,000
Common stock, par value	$ 0.001				$ 0.001	$ 0.001	$ 0.001
Number of common stock shares issued				379,474
Value of common stock shares issued				$ 1,264	$ 297	$ 7,756
Vested in April 2021 [Member]
Restricted stock vested percentage						100.00%
RSA To New Employee [Member]
Stock-based compensation, shares			15,190
Restricted stock vested percentage			25.00%
Employee Stock Purchase Plan [Member]
Number of stock issued for exercise of stock options	14,005
2018 Equity Incentive Plan [Member]
Number of stock issued for exercise of stock options						69,878
Securities Purchase Agreements [Member]
Sale of stock, number of shares issued in transaction		2,600,000		2,600,000
Sale of stock, price per share		$ 3.00	$ 3.00	$ 3.00
Proceeds from sale of stock, consideration received on transaction		$ 7,756		$ 7,756

Share-Based Payment Awards (Details Narrative) $ / shares in Units, $ in Thousands		3 Months Ended			6 Months Ended		12 Months Ended
	Jun. 30, 2018	Jun. 30, 2020 USD ($) shares	Jun. 30, 2019 USD ($) shares	Sep. 30, 2017 Director shares	Jun. 30, 2020 USD ($) $ / shares shares	Jun. 30, 2019 USD ($) $ / shares shares	Dec. 31, 2019 USD ($)	Dec. 31, 2018 shares	May 31, 2017 shares
Stock options expiration period					10 years
Stock-based compensation expense \| $		$ 714	$ 505		$ 1,079	$ 850
Expected dividend yield					0.00%	0.00%
General and Administrative Expense [Member]
Stock-based compensation expense \| $		651	421		$ 976	$ 690
Research and Development Expense [Member]
Stock-based compensation expense \| $		$ 63	$ 84		$ 103	$ 160
Common Stock [Member]
Stock option exercises, shares		64,878	70,000		69,878	90,000
Employee stock purchase plan, shares		14,005	23,083		14,005	23,083
Four Stock Options [Member]
Stock option exercises, shares					69,878	90,000
Exercise price of stock option \| $ / shares					$ 1.39	$ 0.86
Stock option intrinsic value \| $					$ 139	$ 599
Product Consultant [Member]
Number of stock options issued to purchase common stock					50,000
Product Consultant [Member] \| Common Stock [Member]
Stock options expiration period					5 years
Restricted Stock [Member]
Shares issued as compensation				100,000
Restricted Stock [Member] \| Outside Directors One [Member]
Shares issued as compensation				25,000
Restricted Stock [Member] \| Outside Directors Two [Member]
Shares issued as compensation				25,000
Restricted Stock [Member] \| Outside Directors Three [Member]
Shares issued as compensation				25,000
Restricted Stock [Member] \| Outside Directors Four [Member]
Shares issued as compensation				25,000
Restricted Stock [Member] \| Four Outside Directors [Member]
Number of outside directors \| Director				4
Restricted shares to outside directors vesting percentage	100.00%
Stock Option [Member]
Stock options expiration period					10 years
Non-Vested Stock Option Awards and Restricted Awards [Member]
Unrecognized compensation costs \| $		$ 5,160			$ 5,160
2017 Equity Incentive Plan [Member]
Share-based compensation arrangement by share-based payment award, number of shares authorized									5,000,000
2018 Equity Incentive Plan [Member]
Share-based compensation arrangement, shares available for future issuance		510,746			510,746
Stock option exercises, shares					69,878
2018 Equity Incentive Plan [Member] \| January 1, 2019 and Through January 1, 2028
Percentage for total number of shares outstanding							4.00%
2018 Employee Stock Purchase Plan [Member]
Share-based compensation arrangement, shares available for future issuance		391,110			391,110			150,000
Stock-based compensation expense \| $					$ 33	$ 75
Share based compensation for initial shares reserve, description					The Company's ESPP provides for an initial reserve of 150,000 shares and this reserve is automatically increased on January 1 of each year by the lesser of 1% of the outstanding common shares at December 31 of the preceding year or 150,000 shares, subject to reduction at the discretion of the Company's board of directors.
Percentage for purchase stock and fair value of common stock					85.00%
Description for deductions to purchase stock at price per share					After the initial offering period ended, subsequent twelve-month offering periods automatically commence over the term of the ESPP on the day that immediately follows the conclusion of the preceding offering, each consisting of two purchase periods approximately six months in duration.
Employee stock purchase plan, shares					14,005	23,083
Weighted average grant date fair value issued \| $ / shares					$ 2.43	$ 2.57
Employees contribution amount \| $					$ 66	$ 141
Accrued liabilities for remaining employee contributions \| $		$ 9			$ 9		$ 16

Share-Based Payment Awards - Summary of Stock Option Activity (Details) - Stock Option [Member] $ / shares in Units, $ in Thousands	6 Months Ended
	Jun. 30, 2020 USD ($) $ / shares shares
Shares, Options Outstanding, Beginning Balance \| shares	1,829,878
Shares, Issued \| shares	1,302,000
Shares, Exercised \| shares	(69,878)
Shares, Forfeited/Cancelled \| shares	(225,000)
Shares, Options Outstanding, Ending Balance \| shares	2,837,000
Shares, Options Exercisable, Ending Balance \| shares	895,521
Shares, Options Vested and Expected to Vest, Ending Balance \| shares	2,787,000
Weighted Average Exercise Price, Options Outstanding, Beginning Balance \| $ / shares	$ 4.01
Weighted Average Exercise Price, Issued \| $ / shares	3.65
Weighted Average Exercise Price, Exercised \| $ / shares	1.39
Weighted Average Exercise Price, Forfeited/Cancelled \| $ / shares	5.86
Weighted Average Exercise Price, Options Outstanding, Ending Balance \| $ / shares	3.76
Weighted Average Exercise Price, Options Exercisable, Ending Balance \| $ / shares	3.65
Weighted Average Exercise Price, Options Vested and Expected to Vest, Ending Balance \| $ / shares	$ 3.81
Weighted Average Remaining Contractual Term, Options Outstanding, Beginning Balance	8 years 1 month 6 days
Weighted Average Remaining Contractual Term, Options Outstanding, Ending Balance	8 years 7 months 6 days
Weighted Average Remaining Contractual Term, Options Exercisable, Ending Balance	7 years 8 months 12 days
Weighted Average Remaining Contractual Term, Options Vested and Expected to Vest, Ending Balance	8 years 7 months 6 days
Aggregate Intrinsic Value, Options Outstanding, Beginning Balance \| $	$ 6,014
Aggregate Intrinsic Value, Options Outstanding, Ending Balance \| $	5,949
Aggregate Intrinsic Value, Options Exercisable, Ending Balance \| $	2,177
Aggregate Intrinsic Value, Options Vested and Expected to Vest, Ending Balance \| $	$ 5,746

Related Party Transactions (Details Narrative) $ / shares in Units, $ in Thousands					1 Months Ended	3 Months Ended		6 Months Ended		12 Months Ended
	Feb. 18, 2019 USD ($)	Nov. 17, 2017	Aug. 11, 2017 USD ($)	Jun. 23, 2017 USD ($)	Apr. 30, 2019 USD ($)	Jun. 30, 2020 USD ($) Products $ / shares shares	Jun. 30, 2019 USD ($)	Jun. 30, 2020 USD ($) Products $ / shares shares	Jun. 30, 2019 USD ($)	Dec. 31, 2018 shares	Dec. 31, 2019 $ / shares shares
Common stock issued \| shares						20,956,033		20,956,033			17,877,486
Common stock par value per share \| $ / shares						$ 0.001		$ 0.001			$ 0.001
Payment of research and development expense						$ 1,609	$ 1,439	$ 7,877	$ 7,904
Credit agreement term		10 years
Amended and Restated Agreement [Member] \| Maximum [Member]
Royalties	$ 2,000
Amended and Restated Agreement [Member] \| One Milestone [Member]
Related party transaction	250
Amended and Restated Agreement [Member] \| Two Milestone [Member]
Related party transaction	$ 500
Harrow Health Inc [Member]
Common stock issued \| shares						3,500,000		3,500,000
Common stock par value per share \| $ / shares						$ 0.001		$ 0.001
Number of products \| Products						2		2
Harrow Health Inc [Member] \| Common Stock [Member]
Restricted stock award forfeited \| shares										20,000
Harrow Health Inc [Member] \| Restricted Stock [Member]
Number of restricted common stock issued for services \| shares								1,500,000
Number of stock options issued to purchase common stock \| shares								130,000
Eyemax, LLC [Member]
Payment of research and development expense			$ 250
Sale of product expense			$ 500
Percentage of royalty fee			10.00%
Related party transaction			$ 250
Credit agreement term			10 years
Related party transaction, description			The Eyemax Agreement was for an initial term of 10 years from the date of the Eyemax Agreement, subject to successive two-year renewals unless the Company elected to terminate the Eyemax Agreement. There were no amounts due under the terms of the Eyemax Agreement as of June 30, 2020 or December 31, 2019.
Selenix LLC [Member]
Payment of research and development expense				$ 1,500
Sale of product expense				$ 1,000
Percentage of royalty fee				50.00%
Related party transaction					$ 1,500
Credit agreement term				10 years

Commitments and Contingencies (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands						1 Months Ended		3 Months Ended		6 Months Ended		12 Months Ended
	Mar. 26, 2020	Jun. 12, 2019	Feb. 08, 2019	Jan. 23, 2019	Nov. 17, 2017	Mar. 31, 2020	Dec. 31, 2019	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Litigation and management expense					62.50%
Credit agreement term					10 years
Percentage of right to recoup								35.00%		35.00%
Payments for development								$ 1,609	$ 1,439	$ 7,877	$ 7,904
Number of common stock shares issued						379,474
Value of common stock shares issued						$ 1,264		$ 297		7,756
Exclusive License and Supply Agreement [Member]
Cash paid for licensing milestone fee	$ 3,500
Number of common stock shares issued	379,474
Value of common stock shares issued	$ 1,264
Shares issued price per share	$ 3.33
Aggregate value of licensing milestone amount included in research and development expense										$ 4,764
Exclusive License and Supply Agreement [Member] \| Licensor [Member]
Credit agreement term										10 years
Percentage of right to recoup								60.00%		60.00%
Percentage of net profits payments to third party from sale of product								35.00%		35.00%
Payments for development										$ 350
Exclusive License and Supply Agreement [Member] \| Licensor [Member] \| Upon FDA Acceptance [Member]
Payments for development										1,500
Exclusive License and Supply Agreement [Member] \| Licensor [Member] \| Upon FDA Approval [Member]
Payments for development										1,000
Exclusive License and Supply Agreement [Member] \| Licensor [Member] \| Upon Issuance of Patent Covering [Member]
Payments for development										1,500
Exclusive License and Supply Agreement [Member] \| Licensor [Member] \| Product Sales [Member]
Payments for development										500
Exclusive License and Supply Agreement [Member] \| Licensor [Member] \| Calendar Year [Member]
Payments for development										$ 10,000
Licensing and Supply Agreement [Member] \| Licensor [Member]
Credit agreement term				10 years
Percentage of net profits payments to third party from sale of product				35.00%
Payments for development				$ 350
Licensing and Supply Agreement [Member] \| Licensor [Member] \| Upon FDA Acceptance [Member]
Payments for development				325
Licensing and Supply Agreement [Member] \| Licensor [Member] \| Upon FDA Approval [Member]
Payments for development				325
Licensing and Supply Agreement [Member] \| Licensor [Member] \| Upon Issuance of Patent Covering [Member]
Payments for development				650
Licensing and Supply Agreement [Member] \| Licensor [Member] \| Product Sales [Member]
Payments for development				500
Licensing and Supply Agreement [Member] \| Licensor [Member] \| Calendar Year [Member]
Payments for development				10,000
Licensing and Supply Agreement [Member] \| Licensor [Member] \| Upon Successful Bioequivalence Study [Member]
Payments for development				$ 350
Exclusive License and Supply Agreement (ET-202 ) [Member]
Percentage for additional profit												50.00%
Exclusive License and Supply Agreement (ET-202 ) [Member] \| Sintetica [Member]
Payment of licensing												$ 2,000
Percentage of net sales as marketing fees												5.00%
Proceeds from licensing												$ 500
Percentage for additional profit												50.00%
Exclusive License and Supply Agreement (ET-202 ) [Member] \| Upon FDA Approval [Member]
Payment of licensing							$ 750
Exclusive License and Supply Agreement (ET-203 ) [Member]
Percentage for additional profit			50.00%
Exclusive License and Supply Agreement (ET-203 ) [Member] \| Sintetica [Member]
Payment of licensing			$ 1,000
Percentage of net sales as marketing fees			5.00%
Proceeds from licensing			$ 500
Percentage for additional profit			50.00%
Exclusive License and Supply Agreement (ET-203 ) [Member] \| Upon FDA Approval [Member]
Payment of licensing			$ 750
Exclusive License and Supply Agreement (ET-105 ) [Member]
Payment of licensing		$ 2,000
Milestone payment description		$1,000 when net sales exceed $10 million in a calendar year, $2,000 when net sales exceed $20 million in a calendar year, $5,000 when net sales exceed $50 million in a calendar year, $10,000 when net sales exceed $100 million in a calendar year
Exclusive License and Supply Agreement (ET-105 ) [Member] \| Maximum [Member]
Milestone payment amount		$ 18,000
Exclusive License and Supply Agreement (ET-105 ) [Member] \| Upon FDA Approval [Member]
Payment of licensing		2,000
Exclusive License and Supply Agreement (ET-105 ) [Member] \| Upon Issuance of Orange-book Listed Patent [Member]
Payment of licensing		1,000
Exclusive License and Supply Agreement (ET-105 ) [Member] \| Scenario One [Member]
Milestone payment amount		1,000
Exclusive License and Supply Agreement (ET-105 ) [Member] \| Scenario One [Member] \| Minimum [Member]
Net sales		10,000
Exclusive License and Supply Agreement (ET-105 ) [Member] \| Scenario Two [Member]
Milestone payment amount		2,000
Exclusive License and Supply Agreement (ET-105 ) [Member] \| Scenario Two [Member] \| Minimum [Member]
Net sales		20,000
Exclusive License and Supply Agreement (ET-105 ) [Member] \| Scenario Three [Member]
Milestone payment amount		5,000
Exclusive License and Supply Agreement (ET-105 ) [Member] \| Scenario Three [Member] \| Minimum [Member]
Net sales		50,000
Exclusive License and Supply Agreement (ET-105 ) [Member] \| Scenario Four [Member]
Milestone payment amount		10,000
Exclusive License and Supply Agreement (ET-105 ) [Member] \| Scenario Four [Member] \| Minimum [Member]
Net sales		$ 100,000

Company Overview (Details Narrative) - USD ($) $ in Thousands	1 Months Ended			6 Months Ended
	Nov. 30, 2019	Nov. 30, 2018	Jun. 30, 2017	Jun. 30, 2020	Jun. 30, 2019
Start-up capital			$ 20,055
Proceeds from loan offering	$ 4,750
Proceeds from sale of shares of common stock				$ 7,756
Initial Public Offering [Member]
Net cash proceeds from initial public offering		$ 21,960

Common Stock Warrants - Summary of Warrants Outstanding (Details)	Jun. 30, 2020 $ / shares shares
No. of Shares, Total \| shares	1,672,335
Exercise Price \| $ / shares	$ 3.13
Business Advisory Warrants [Member]
No. of Shares, Total \| shares	600,000
Exercise Price \| $ / shares	$ 0.01
Placement Agent Warrants - 2017 Preferred Stock Offering [Member]
No. of Shares, Total \| shares	607,096
Exercise Price \| $ / shares	$ 3.00
Placement Agent Warrants - IPO [Member]
No. of Shares, Total \| shares	414,000
Exercise Price \| $ / shares	$ 7.50
SWK Warrants - Debt [Member]
No. of Shares, Total \| shares	51,239
Exercise Price \| $ / shares	$ 5.86

Leases - Schedule of Lease-related Assets and Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Total leased assets	$ 96	$ 160
Operating Lease Right-of-use Assets [Member]
Total leased assets	96
Accrued Liabilities [Member]
Total operating lease liabilities	87
Operating Lease Liability [Member]
Total operating lease liabilities	$ 87

Subsequent Events (Details Narrative) - Subsequent Event [Member] $ in Thousands	Aug. 11, 2020 USD ($)
Line of credit	$ 2,000
Minimum [Member]
Line of credit facility, maximum borrowing capacity	10,000
Maximum [Member]
Line of credit facility, maximum borrowing capacity	$ 15,000

Condensed Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2020	Dec. 31, 2019
Statement of Financial Position [Abstract]
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	50,000,000	50,000,000
Common stock, shares issued	20,956,033	17,877,486
Common stock, shares outstanding	20,956,033	17,877,486

Leases (Details Narrative) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
Leases (Details Narrative) - USD ($) $ in Thousands	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Incremental borrowing rate	7.80%		7.80%
Operating lease payment			$ 65
Amortization rights to use of assets			$ 33	$ 64
ROU asset amortization		$ 59		30
Weighted-average remaining lease term	8 months 12 days		8 months 12 days
Weighted-average incremental borrowing rate	7.80%		7.80%
Research and Development Expense [Member]
Operating lease cost	$ 14	14	$ 28	28
General and Administrative Expense [Member]
Operating lease cost	$ 20	$ 20	$ 41	$ 43

Leases - Schedule of Lease Commitments (Details) $ in Thousands	Jun. 30, 2020 USD ($)
2021	$ 607
Operating Lease Liability [Member]
2020	70
2021	19
2022
Thereafter
Undiscounted lease payments	89
Less: Imputed interest	(2)
Total lease liabilities	$ 87